Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer
Pradipta Ghosh, Jeanne Tie, Andrea Muranyi, Shalini Singh, Patrick Brunhoeber, Katherine Leith, Rebecca Bowermaster, Zhiming Liao, Yifei Zhu, Bonnie LaFleur, Ben Tran, Jayesh Desai, Ian Jones, Matthew Croxford, Rodrigo Jover, Ajay Goel, Paul Waring, Song Hu, Volker Teichgraber, Ulrich-Peter Rohr Show all
Clinical Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2016
Awarded by NIH
Awarded by seed grant from the Moores Cancer Center
This work was supported by Ventana Medical Systems, Inc., the NIH (R01CA160911 and R01 CA100768, to P. Ghosh; R01 CA72851, CA 181572, and U01 CA187956, to A. Goel), and seed grant from the Moores Cancer Center (P30CA23100, to P. Ghosh) and the Baylor Research Institute (to A. Goel).